Revealed: Chinese companies’ IP strategies

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Revealed: Chinese companies’ IP strategies

cover-puff.jpg

Managing IP’s biggest ever survey of Chinese in-house counsel reveals their IP filing plans, experience with litigation and policies on hiring foreign firms. Peter Leung spoke to ZTE, JK Sucralose, Livzon Pharmaceutical and other respondents to get the details

How much do you expect your foreign filing budget to grow next year?

null

null

The 2012 Chinese in-house survey was conducted at Managing IP's third IP Forum for Chinese IP counsel in Beijing, which was attended by more than 400 companies. The results underscore the increase in Chinese outbound work, revealing much about the types of companies making the move overseas and how they manage their IP portfolios. Four out of five of the 130 respondents said their budget for protecting IP rights abroad had increased in the past year, with some saying it had more than doubled (see chart, above).

There is no single profile that fits the Chinese companies looking to expand overseas; they come from a wide variety of industries and they structure their IP in a range of ways. However, the data and subsequent interviews do reveal some common themes.

Chinese businesses contemplating overseas expansion are cautious and diligent in the way they manage their IP. What sets them apart from peers in more developed economies is a particularly strong emphasis on the need for preventative measures and research that allows them to anticipate problems and minimise litigation risks. Chinese companies also seek external counsel who understand their business goals, and that the legal work is just one part of a larger strategy.

Analysis of the results of the survey, the raw data and case studies with companies ZTE and JK Sucralose are available at the links below. The first is free to access but you must be a subscriber to see the data and the case studies.

As ever, there is discussion of the results on the Managing IP Twitter account. Use the hash tag #MIPChinaSurvey. Please tell us your opinion on China and its IP either there or using the comment button at the top of this story.

We are also preparing the survey for next year, which will be used at the 2013 Beijing and Shanghai events. If there are any questions you think would be interesting to add to the survey, please email us at mip@managingip.com. Anyone suggesting a question will receive free access to the sections of the survey otherwise only available to subscribers. 

China in-house survey contents

1. Introduction and methodology

2. Analysis: aggressive expansion, cautious IP

3. Case study: Alex An, JK Sucralose on winning at the ITC

4. Case study: Alvin Shen, ZTE on managing its IP abroad

5. The data:


more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article